Carbamazepine is a commonly prescribed anti-epileptic drug. Rarer indications for carbamazepine therapy include trigeminal neuralgia and mood disorders.
Under normal physiological circumstances, 75-80% of the measured circulating carbamazepine is bound to plasma proteins. A free carbamazepine assay is also available and may provide useful additional information in those with an abnormal plasma protein concentration, or in those taking additional protein-bound drugs.
For a full list of brand names for this drug used in NZ, please see the relevant entry in the NZ Formulary
A trough sample should be collected (i.e. taken immediately before the next dose is due).
Drug levels should not be taken until steady state pharmacokinetics have been achieved (i.e. at least 4-5 half-lives after starting the drug/changing dose - the half-life of carbamazepine is approximately 15 hours).
Chilled (2 - 8 degrees Celsius)
If overnight - Chilled (2 - 8 degrees Celsius)
The standard half-life of carbamazepine is 15 hours, with time to steady-state of 3 days.
Refer to the CDHB Therapeutic Drug Monitoring Profiles for advice on how to interpret carbamazepine levels.
The above ranges are a guide only. The target plasma concentration should be tailored to the individual patient in accordance with clinical features of efficacy and/or drug toxicity. Consultation with the clinical pharmacology team is recommended if expert advice is required.
Performed on Beckman Coulter AU5822 analyser using Beckman Coulter reagents.
$21.42 (Exclusive of GST)
Grossly haemolysed specimens are unsuitable for analysis.
"*" indicates required fields